Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Epigenetic Profiling and Telomere-Orchestrated Mechanisms in HPV+ Oropharyngeal Cancer

Project description

Epigenetics in HPV-associated cancer

Human papillomavirus (HPV)-positive oropharyngeal cancer is a rapidly rising subtype of head and neck cancer, driven by HPV infection rather than tobacco or alcohol. While prognosis is generally favourable, a significant proportion of patients relapse or develop metastases, reflecting considerable variability in tumour behaviour that current tools cannot predict. With the support of the Marie Skłodowska-Curie Actions programme, the EPiTOME-M project will focus on the epigenetic mechanisms underlying this variability. Researchers will use single-cell DNA methylation profiling, patient-derived organoids and CRISPR-based tools to identify cell-type-specific epigenetic signatures. Moreover, they will map regulatory DNA structures and examine how telomere length influences immune responses within the tumour. Findings will enable novel biomarker discovery and improve patient stratification for personalised treatment.

Objective

HPV-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC) is a rapidly rising, clinically distinct subtype of head and neck cancer. Despite favourable prognosis, 1/3rd of patients relapse and 5–13% develop metastases within 3 years, reflecting marked interpatient and intra-tumoral heterogeneity and thus impacting treatment response. EPiTOME-M aims to address this challenge by identifying the cell of origin and dissecting epigenetic mechanisms driving heterogeneity and immune evasion. Current studies rely on bulk sequencing, which mask cell-type–specific signals and spatial complexity. I will apply sciMET-seq, a single-cell DNA methylation technology to create reference methylomes from normal tonsil and HPV+ OPSCC tissues, to identify lineage-specific epigenetic signatures. Building on this, I will map G-quadruplex (G4) structures—non-canonical DNA elements known to modulate methylation—within differentially methylated regions and test their functional impact using CRISPRi in HPV˖ OPSCC cell lines. Additionally, I will use patient-derived organoids to examine how telomere length influences the tumour immune microenvironment. This multidisciplinary approach—combining epigenomics, telomere biology, and immunology—will yield mechanistic insights into tumour heterogeneity and immune modulation, enabling novel biomarker discovery and precision stratification in HPV˖ OPSCC. The project will foster a two-way knowledge exchange between me and the host institutions, RCSI and secondment host KU Leuven. This includes expertise in DNA methylation and biomarker development, clinical insight and sample access (RCSI), telomere biology expertise (my contribution), and training in single-cell genomics (KU Leuven). Ultimately, by integrating these strengths, the fellowship will empower me to address a critical question in HPV+ OPSCC and establish a strong, independent research profile at the interface of telomere biology, epigenomics, and oncology.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND
Net EU contribution
€ 268 568,64
Address
ST STEPHEN GREER 123
D02 YN77 DUBLIN 2
Ireland
Region
Ireland Eastern and Midland Dublin
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (1)